Warnings about the potential threats of artificial intelligence (AI) technology have been coming thick and fast from a wide range of industries.
But the use of cutting-edge AI could benefit us all by dramatically speeding up the development of new medicines in a ‘game- changing’ moment for the sector, according to one of Britain’s biggest drug firms.
GlaxoSmithKline has begun using AI – which recently shot to prominence amid the growing popularity of websites such as ChatGPT – to make its medical treatments more personalised for individual patients, which in turn can increase the effectiveness of drugs.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
